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High oncogenic risk human papillomaviruses (HR-HPVs) promote cervical carcinoma
development, the fourth most common feminine cancer. A slow oncodevelopmental
phase—defined histopathologically as Cervical Intraepithelial Neoplasia (CIN) grades
1–3, or cytologically as Low- or High-grade Squamous Intraepithelial Lesions (LSIL
or HSIL)—precedes the malignancy. Cervical carcinoma screenings through HR-HPV
genotyping and Pap smears are regularly performed inWestern countries. Faulty cytology
screening or genotyping or patients’ non-compliance with follow-ups can let slip an
oncoprogression diagnosis. Novel biomarker tests flanking HR-HPV genotyping and
cytology could objectively predict the risk of disease progression thus helping triage
LSIL/ASCUS patients. Here, anonymized leftovers of fresh cervical epithelium scrapings
from twice (LSIL/ASCUS and HR-HPV DNA)-positive and twice (Pap smear- and
HR-HPV DNA)-negative (control) patients in a proteome-preserving solution served to
assess the biomarker worth of three cervical carcinoma-related proteins, i.e., B-MYB
(or MYBL2), Cancerous Inhibitor of PP2A (CIP-2a), and transketolase-like1 (TKTL1).
Leftovers anonymity was strictly kept and storage at −80◦C, protein extraction,
immunoblotting, and band densitometry were blindly performed. Only after tests
completion, the anonymous yet code-corresponding HR-HPV-genotyping and cytology
data allowed to assign each sample to the twice-positive or twice-negative group.
Descriptive statistics showed that the three proteins levels significantly increased in the
twice-positive vs. twice-negative scrapings. Diagnostic ROC curve analysis identified
each protein’s Optimal Decision Threshold (OTD) showing that TKTL1 and CIP-2a are
stronger risk predictive biomarkers (Sensitivity, 0.91–0.93; Specificity, 0.77–0.83) than
B-MYB. Logistic Regression coupled with Likelihood-Ratio Tests confirmed that a highly
significant relation links increasing TKTL1/CIP-2a/B-MYB protein levels in twice-positive
cervical scrapings to the risk of HR-HPV-driven oncoprogression. Finally, a 3 year
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clinical follow-up showed that 13 patients (50% of total) of the twice-positive group
with biomarker values over OTDs compliantly underwent scheduled colposcopy
and biopsy. Of these, 11 (i.e., 84.7%) received a positive histological diagnosis,
i.e., CIN1 (n = 5; 38.5%) or CIN2/CIN2+ (n = 6; 46,2%). Therefore, TKTL1/CIP-
2a/B-MYB protein levels could objectively predict oncoprogression risk in twice
(HR-HPV- and Pap smear)-positive women. Further studies will assess the translatability
of these findings into clinical settings.
Keywords: LSIL, ASCUS, human cervical carcinoma, oncogenic papillomaviruses, TKTL1, CIP-2a, B-MYB,
predictive biomarker
INTRODUCTION
Human papillomavirus (HPV) infections drive ∼5% of all
human cancers (1). So far, DNA sequence information has
identified more than 200 HPV genotypes (2–4). Of these,
51 are sexually transmitted mucosal α-HPV genotypes which,
according to their epidemiological association with cancers of
uterine cervix, vagina, vulva, anus, and penis, are gathered in
three subtype groups: (i) high-risk HPVs (HR-HPVs); (ii) likely
HR-HPVs (l-HR-HPVs); and (iii) low-risk HPVs (LR-HPVs) (5,
6). Additionally, cutaneous β-HPV genotypes, may cause skin
warts and cancers (7–10). An acute infection due to HR o
LR-HPVs spontaneously heals within 2–3 years in ∼90% of
the patients. However, concurring co-factors (e.g., smoking,
oral contraceptives, pregnancy, Herpes virus type 2 infections,
etc.) may promote a persisting HR-HPV integration into the
infected cells’ genome triggering an oncogenic progression in
the remaining ∼10% of cases (11–14). Notably, human cervical
carcinoma is the fourth most common female cancer worldwide
(11, 15). These malignancies are generally preceded by a pre-
invasive or in situ disease, defined (i) via histopathological
criteria as Cervical Intraepithelial Neoplasia (CIN), distinguished
in three sequential grades, i.e., CIN1, CIN2, and CIN3; and (ii)
via cytological criteria as Low-grade- or High-grade Squamous
Intraepithelial Lesions (LSIL or HSIL, respectively) or as Atypical
Squamous Lesions of Undetermined Significance (ASCUS) (14,
16). Typically, a fraction of the women diagnosed with
LSIL or ASCUS lesions may have an underlying CIN grade
histopathology or a cervical carcinoma (17, 18). The best
management options for such LSIL or ASCUS women are
controversial (19, 20). Moreover, a discrete fraction of non-
compliant patients drops from any proposed follow-up program
(21, 22). Hence, although it should be the first choice when
patient’s compliance is uncertain, direct colposcopy referral for
all LSIL/ASCUS cases would mostly detect only minor dysplasia
Abbreviations: ASCUS, atypical squamous lesions of undetermined significance;
AUC, area under the (ROC) curve; 95% CI, 95% confidence interval; CIN, cervical
intraepithelial neoplasia; CIP-2a, cancerous inhibitor of PP2A; FN, false negative;
FP, false positive; GISCI, Italian Association of Cervical Screening Programs; HPV,
human papilloma virus; HR-HPV, high-risk HPV; HSIL, high-grade squamous
intraepithelial lesion; LR-HPV, low-risk HPV; LRT, likelihood ratio test; LSIL, low-
grade squamous intraepithelial lesion; ODT, optimal decision threshold; ROC,
receiver operator characteristic; TKTL1, transketolase-like1; TNF, true negative
fraction (or specificity); TPF, true positive fraction (or sensitivity).
(23). Conversely, a negative cytological misdiagnosis would delay
proper treatment (24). Then again, a negative HR-HPVDNA test
might be more falsely reassuring than a negative cytological test
(25). Finally, present genotyping does not cover oncogenic l-HR-
and LR-HPV subtypes.
Each Western country addresses this somewhat murky
diagnostic situation differently. The Italian Association of
Cervical Screening Programs (GISCI) binding guidelines
emphasize the need for using first the HR-HPV genotyping
followed, if positive, by the cytology test and again,
if positive, by colposcopy; negative women should be
retested after 1–3 years (26, 27). However, it would
be both scientifically and clinically helpful to rely also
upon specific biomarkers objectively predicting the actual
risk of progression for any cytological precancerous
lesion in HR-HPV DNA-positive and Pap smear-positive
patients (22, 28).
Therefore, the present work aimed at assessing the potential
worth of three proteins—i.e., B-MYB (or MYBL2), Cancerous
Inhibitor of PP2A (CIP-2a), and transketolase-like1 (TKTL1)—as
risk predictive biomarkers of disease progression.We chose these
proteins because they are over expressed in advanced dysplastic
lesions and cervical carcinomas [(13, 29–35); see the Discussion
for more details]. We used as starting materials, under strictly
anonymized conditions, the leftovers of cervical epithelium
scrapings from HR-HPV DNA-positive and LSIL/ASCUS
diagnosed (i.e., twice-positive) patients and, as controls (Ctr),
scraped leftovers from HPV DNA-negative and Pap smear-
negative (i.e., twice-negative) patients. Our herein reported
biochemical results integrated by the results of a subsequent
3-year follow-up of the compliant fraction (50%) of the same
twice-positive patients indicate that increases in TKTL1, CIP-
2a, and B-MYB proteins above their respective Optimal Decision
Threshold (ODT) valuesmay robustly predict the risk of an active
HR-HPV-driven oncogenesis.
MATERIALS AND METHODS
Samples
Following the suggestions of European Union guidelines,
population-based organized cervical screening programs have
been ongoing since 1998 in the Veneto and Trentino-Alto
Adige Regions (North-East Italy) (36–38). Every 3 or 5,
years women aged 19–64 are invited to undergo Pap smear
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cytology and HPV-DNA genotyping at no personal expense.
The screening procedures are organized and overseen by the
Local Healthcare Units. The screening protocol follows the
GISCI guidelines (26) and a Health Technology Assessment
Report on HPV DNA-based primary screening (27). Besides
the official letter of invitation, the eligible women receive an
a leaflet with information about HPVs, the HR-HPV test, and
the screening program. If women do not act in response to
the first invitation, they receive a second informing reminder
by mail. Women coming of their own accord to the Hospital
test site sign the informed consent prior to the sampling of
their cervical cells. The collection of the anonymized leftover
samples of human cervical epithelial cells took place in Veneto
and Trentino Hospitals. Given the particular study type ethical
review and approval was not required as per local legislation.
Just after sampling, the cervical leftovers were dipped into a
freezing solution (90%v/v fetal bovine serum (FBS) + 10%v/v
DMSO), coded to anonymize them, and next stored at −80◦C
until brought to our lab where they received the second
coding. Preliminary investigations (not detailed here) led to
choose the FBS+DMSO freezing solution as it preserved the
integrity of the cervical cells’ proteome. Several other commercial
solutions evaluated in parallel, which contained organic and
fixative solvents (e.g., Thin PrepTM Hologic USA, CytofastTM
Hospitex International Italy, etc.), could not preserve the cells’
proteome integrity. HR-HPV DNA genotyping and Pap smear
cytology tests were carried out on portions of the original
scrapings having the same code as their leftover counterparts
at the laboratory services of the Hospitals involved. However,
information about the age, HR-HPV DNA genotype(s), and Pap
smear diagnosis was kept strictly secret until all the leftovers
had undergone the protein immunoblotting tests and their
densitometric evaluations. Leftovers with an inadequate protein
amount were directly cast out. Leftovers whose HR-HPV DNA
genotype could not be retrieved were also disposed of. Leftovers
with coexisting infectious conditions other than HR-HPVs were
too left out. However, the data from six pilot samples with a
cytological diagnosis of inflammation but with a negative result
of a complete TVAG (Trichomonas, Candida, Bacterial vaginosis,
Chlamydia, and Mycoplasma) test were kept apart as specificity
controls. Eventually, 16 both PAP smear-negative and HR-HPV-
DNA-negative [“twice-negative” or control (CTR)] samples, and
26 LSIL/ASCUS and HR-HPV-DNA positive (“twice-positive”)
samples constituted the main populations studied. Their mean
age was for both groups was 34.5 years with a range from 16 to
56 years. Cytological diagnoses proportions were: LSIL, 2/3 and
ASCUS, 1/3 of the total cases. LSIL and ASCUS data were pooled
together because of the limited numbers of the latter. Moreover,
ASCUS HPV-DNA-positive patients were categorized together
with LSIL ones because GISCI’s guideline indicates that the
ASCUS diagnostic category, being borderline, must be avoided
or limited to a minimum, and the relative samples classified
as clearly as possible as LSIL or negative (26, 27). No samples
from patients diagnosed as positive for the HR-HPV molecular
test and HSIL or ASC-H were obtained as they were directly
referred to colposcopy.
Samples Lysis
This procedure and the subsequent Western immunoblotting
was carried out on the anonymized leftover samples blindly,
i.e., with no knowledge of their cytological and HR-HPV DNA
characteristics. Frozen leftover samples were fast thawed at
45◦C and next spun at 200 × g for 10min at 4◦C. The
resulting pellets were resuspended in 1.0ml of phosphate buffer
saline (PBS) added with complete EDTA–free protease inhibitor
cocktail (Roche, Milan). The cells’ morphological integrity was
checked under an inverted phase-contrast light microscope
(IM35, Zeiss). Next, after three washings with PBS + anti-
proteolytic cocktail, cell pellets were homogenized in T–PERTM
tissue protein extraction reagent (Thermo Scientific, Rockford,
USA) also added with the complete EDTA–free protease inhibitor
cocktail. Finally, to achieve total cell lysis samples were subjected
to one freeze/thaw cycle at −20◦C and ice-homogenized with an
UltraTurraxTM. The protein contents of the extracts were assayed
according to Chiarini et al. (39, 40) using bovine serum albumin
(BSA) as standard.
Western Immunoblotting (WB)
WB was performed as detailed in Chiarini et al. (39, 40).
Equal amounts of protein lysates (15 µg for the analysis
of TKTL1 and CIP-2a and 20 µg for B-MYB) were heat–
denatured for 10-min at 70◦C in an appropriate volume of 1X
NuPAGE LDS Sample Buffer supplemented with 1X NuPAGE
Reducing Agent (Life Technologies, Italia). In parallel, 10 µg
of protein lysate obtained from cervical carcinoma C4-I cells
(39, 40) served as the positive control (PC). The amount of
sample to be loaded was determined for each target protein
to produce a linear signal response for both the target protein
and the loading control (LC). The samples were next loaded
on NuPAGE Novex 4–12% Bis–Tris polyacrylamide gel (Life
Technologies Italia). After electrophoresis in NuPAGE MOPS
SDS Running Buffers using the Xcell SureLockTM Mini–Cell (Life
Technologies Italia) (50min runtime at 200V constant), proteins
were blotted onto nitrocellulose membranes (0.2µm) by means
of iBlotTM Dry Blotting System (Life Technologies Italia). The
membranes were probed with the following rabbit polyclonal
primary antibodies: (a) anti-TKTL1 (ab 155662, Abcam, UK),
diluted 1:1000 in TBST/1% BSA; (b) anti-B-MYB (ab 191064,
Abcam), at the concentration of 0.5 µg ml−1 in TBST/1%
BSA; (c) anti-CIP-2a (ab 99518, ABCAM) diluted 1:1000 in
TBST/1% BSA; (d) anti-β actin mouse monoclonal antibody
(Santa Cruz Biotechnology) which served as loading control
(LC) and was used at 1.0 µg ml−1 in TBST/1% BSA. After
overnight incubation at 4◦C, the membranes were probed with
the secondary, alkaline phosphatase conjugated, donkey anti-
rabbit IgG (Abcam), diluted 1:3000 in TBST or goat anti-
mouse IgG (Thermo) diluted 1:1000 in TBST. BCIP/NBT (cat. #
72091, Sigma) was used as chromogenic blue substrate to detect
alkaline phosphatase activity. The membranes were incubated
in the substrate solution for 10-min until color development;
thereafter, the reaction was stopped by washing the membranes
in several changes of bidistilled water. The membranes were
scanned in an OdisseyTM (LI-COR, Inc. USA) using the 700
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channel. A digital image of each western blot was saved in
TIFF format. The densitometric integrated intensity values of
the specific bands for the B-MYB, CIP-2a, and TKTL1 antigens
and of the loading controls (LC) were evaluated by means of
the Image StudioTM Software, version 5.2, developed by LI-COR
Inc. for WB analysis. The densitometric analysis of the specific
protein bands pertaining to each sample was performed on three
independent immunoblots and the results for each tested protein
were presented as the mean of signal intensities ± SEM. To ease
calculations all densitometric values were multiplied by E4. In
detail, the “Add Rectangle” tool in Image Studio Software served
to draw a rectangular-shaped box around the bands of interest to
quantify the target proteins. The “Median background method”
allowed to compute the median pixels intensity at the border
contouring the band’s shape and to subtract the background from
the shape intensity. Finally, the “Signal value” for each shape was
calculated by determining its “Total signal” and by subtracting
from the latter the product of the “Background” multiplied for
the “Area.”
Human Cervical Carcinoma C4-I Cells
C4-I cells were plated in 175 cm2 plastic flasks (Sarstedt S.r.l.,
Verona, Italy), and incubated at 37◦C in 95%v/v air/5%v/v
CO2 in a complete medium consisting of 95%v/v Dulbecco’s
modified Eagle’s Minimum Essential Medium (DMEM; Sigma-
Aldrich, Milan, Italy), 5%v/v heat-inactivated (56◦C for 30min)
FBS (Lonza AG, Basel, Switzerland), and gentamycin (0.1mg
ml−1; Lonza). Before reaching confluence, cultures were split at
a ratio of 1:6 after briefly incubating them at 18 ± 2◦C with
0.025% (w/v) trypsin (Sigma-Aldrich). Protein extracts from the
cells of six culture flasks were processed as previously detailed
(39, 40) and served as positive controls for B-MYB, CIP-2a, and
TKTL1 proteins.
Cytology and HR-HPV-DNA Genotyping
Pap smear tests were performed on all the cervical epithelium
specimens from which the leftovers derived in the laboratories
of the involved Hospitals. In parallel, the same scrapings were
partly dipped into Thin PrepTM (Hologic USA) to analyze the
genotypes of the infecting HPVs using the INFINITY HPV
QUADTM assay developed by AutoGenomics Inc, (Vista, CA,
USA), which detects HR-HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68 (41) or COBAS HPV test (Roche
Molecular Diagnostics, Pleasanton, CA, USA) which detects HR-
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
and 68. Only after completion of immunoblotting and band
densitometric intensity assessments on all the leftover samples
and prior to be sent to the Verona lab, the results of the
cytological and HR-HPV genotyping and the ages of patients
were anonymized and each labeled with the same code as the
corresponding leftovers. The pairing of the data with the same
code allowed their later assignment to the twice-positive or twice-
negative group to carry out the statistical work-up. Therefore,
no breach of sample anonymity whatsoever took place during all
such procedures.
Statistical Analysis
Descriptive and diagnostic statistical analyses were carried out
using the Analyse-itTM software package (www.analyse-it.com).
Shapiro-Wilk’s test revealed that a normal distribution could
not be assumed for most of the data groups. Welch’s t-test
or Wilcoxon rank Z test (42) were used for the descriptive
statistical comparisons of the densitometric integrated intensity
results concerning each protein’s specific immunoblot bands
from twice-negative controls vs. twice (LSIL/ASCUS and HPV
DNA)-positive groups. For diagnostic statistics a prevalence of
HPV infection of 0.31 was assumed by averaging observations
from whole Italy (43, 44). The performance of diagnostic tests,
i.e., their ability to correctly identify positive and negative cases
over a range of medical decision points, was assessed using non-
parametric empirical receiver-operating characteristic (ROC)
curve analysis (45). The values ± SEMs of the areas under
each ROC curve (AUC) distinguished every sample distribution
vs. the no discrimination or chance area, the latter having a
value of 0.5 (46). Differences between AUC pairs were assessed
via DeLong’s non-parametric Z test (47). Youden’s J index
(or Youden’s statistic), which optimizes biomarker performance
when equal weight is allotted to Sensitivity and Specificity,
was calculated by the non-parametric method of Delong et al.
(48–50). The maximum J index value indicated the Optimal
Decision Thresholds (ODTs) of the densitometric integrated
intensity values for each of the three proteins studied at values
of: Sensitivity, 0.933–0.909; and Specificity, 0.833–0.769 (51).
Finally, binary Logistic Regression was used to independently
confirm that a continuous predictor or explanatory variable
did indeed impact on a dependent binary or dichotomous
variable (52–56). The tests used were two-sided wherever possible
and the level of statistical significance was a P-value < 0.05.
For more details on statistical methods used see the online
Supplemental Material.
RESULTS
The present work aimed at assessing the worth of three proteins,
i.e., B-MYB, CIP-2a, and TKTL1, as risk predictive biomarkers of
HR-HPV-driven precancerous disease progression. Anonymized
fresh cervical epithelium scrapings leftovers which were “twice-
positive” having a cytological diagnosis of LSIL/ASCUS and being
also HR-HPV DNA-positive for 14 different oncogenic subtypes
(see Table 1 for details in this regard) comprised the test group.
As observed also by others (57), multiple HR-HPV subtypes
infections, with HPV-16, -51, -52, and -56 as the more prevalent
ones, occurred in 58% of the leftovers (Table 1). “Twice-negative”
(both Pap test-negative and HR-HPV DNA-negative) specimens
served as controls. To fully preserve the protein complement of
the leftovers an ad hoc freezing medium (90%v/v FBS + 10%v/v
DMSO) was devised and thoroughly tested prior to starting
the study. The results proved its clear superiority over any
other standard commercial solutions containing organic agents
or fixatives, e.g., Thin PrepTM (Hologic, USA), CytofastTM
(Hospitex International, Italy), etc., which were also tested in
parallel (not shown). All the leftovers were processed blindly,
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TABLE 1 | Prevalence of HR-HPV DNA subtypes in twice-positive* cervical
scrapings.
HR-HPV
subtype
Total
samples
Single HR-HPV
infection
Multiple HR-HPV
infections
% multiple infections
vs. total samples
16 10 7 3 33.3
51 6 2 4 12.5
52 5 5 10.4
56 5 5 10.4
18 5 3 2 10.4
31 4 2 2 8.4
66 3 2 1 6.3
35 2 1 1 4.2
39 2 2 4.2
45 2 2 4.2
58 2 1 1 4.2
33 1 1 0
68 1 1 0
*Twice (LSIL/ASCUS and HR-HPV DNA)-positive samples.
and their belonging to the twice-positive or twice-negative
group became known only after immunoblotting procedures and
specific band protein immunoblot densitometry evaluations had
been carried out for all the specimens involved.
Figure 1 shows typical immunoblot bands of the three
putative biomarker proteins studied. The protein bands from
twice (Pap test- andHR-HPV)-negative (Ctr) samples are flanked
by corresponding ones from twice (LSIL/ASCUS and HR-HPV)-
positive samples. Typical matching proteins bands from pre-
metastatic human C4-I cervical carcinoma cells (39, 40) are also
displayed as positive controls (PCs).
In absolute terms, the densitometric integrated intensity
values of B-MYB immunoblot bands were the lowest while those
of CIP-2a the highest ones. In relative terms, the immunoblot
bands mean densitometric values were significantly higher—
B-MYB, 4.7-fold (P = 0.0023); CIP-2a, 7.7-fold (P < 0.0001);
and TKTL1’s 14.6-fold (P < 0.0001)—in the twice (LSIL/ASCUS
and HR-HPV)-positive samples than in their twice-negative
(control) counterparts (Figure 2; Table 2). Therefore, HR-HPV-
infection drove a significant overexpression of the three proteins
with intensities decreasing in the order TKTL1 > CIP-2a > B-
MYB which could be detected through WB and densitometry
evaluations in the LSIL/ASCUS cervical epithelium scrapings.
Receiver operating characteristics (ROC) curves plot the
diagnostic accuracy of a putative biomarker across the whole
range of potential decision thresholds (45, 46). Figure 3 displays
the ROC curves pertaining to each of the three proteins studied.
In each instance, the mean value of the area under the respective
ROC curve (AUC) (47) significantly (P < 0.0001) differed
from the value (= 0.5) of the no discrimination or chance
area (Figure 3; Table 3). Moreover, the three proteins’ AUCs
significantly (P < 0.001) differed from each other, and both
TKTL1’s and CIP-2a’s AUC values were significantly (P < 0.001)
higher than B-MYB’s. This was the first indication that TKTL1
and CIP-2a likely are more robust biomarkers of HR-HPV-driven
FIGURE 1 | The different expression of putative biomarker proteins B-MYB,
CIP-2a, and TKTL1 can be detected in Western immunoblots of cervical
epithelium scraping leftovers from twice (LSIL/ASCUS and HR-HPV
DNA)-positive and twice (HR-HPV DNA- and Pap-test)-negative patients. The
typical immunoblots show also as positive controls (PC) the same proteins as
expressed by pre-metastatic human cervical carcinoma C4-I cells. The loading
control (LC) protein is β-actin. The samples were run on SDS-PAGE and
blotted as detailed in the Materials and Methods section.
risk of disease progression than B-MYB in the twice-positive
cervical epithelium scrapings.
Precision statistical analysis showed how the values of
ROC curve Sensitivity and Specificity and Youden’s J index
(or Youden’s statistic) concomitantly changed for each of the
proteins tested along with increasing densitometric values of
specific protein bands (Figures 4A–C). Notably, Youden’s J
index peak value embodies a criterion to choose the Optimum
Decision Threshold (ODT)—in this case the specific protein
band densitometric integrated intensity values (x E4)—of a
dichotomous (0-to-1) diagnostic numeric test (i.e., normal or
active oncoprogression) (48, 49).
Remarkably, B-MYB’s Youden’s J index peak value, i.e., 0.472
(at 0.913 Specificity, 0.538 Sensitivity, 68.5% Accuracy, with a
Likelihood Ratio (+) of 2.02, a Predictive Value (+) of 0.48, and
a Cost of 0.189) moved to the third rank B-MYB’s candidacy
as a standalone clinically useful biomarker of an active HR-
HPV-driven oncogenesis to be looked for in cervical epithelium
scrapings of twice (LSIL/ASCUS andHR-HPV)-positive patients.
Conversely, CIP-2a’s peak value of Youden’s J index was 0.678
(at 0.909 Sensitivity, 0.769 Specificity, 85.7% Accuracy, with a
Likelihood Ratio (+) of 3.94, Predictive Value (+) of 0.64, and
Cost of 1.40), which put CIP-2a’s biomarker candidacy in the
second rank.
Hence, TKTL1 occupied the first rank as candidate biomarker
since it exhibited a Youden’s J index peak value of 0.833 (at 0.933
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FIGURE 2 | The different expression of putative biomarker proteins B-MYB
(A), CIP-2a (B), and TKTL1 (C) is significantly increased in twice (LSIL/ASCUS
and HR-HPV DNA)-positive fresh cervical epithelium scraping leftovers vs.
twice (normal Pap test/HPV DNA-negative, i.e., controls)-negative samples.
The data are shown as side by side univariate plots of each protein specific
band densitometry values as skeletal notched box charts including from the
first to the third quartiles, with the median indicated by a black transverse line,
and the minimum and maximum values as whiskers with end caps. The box
notch indicates the 95% confidence interval (CI) of the median. A blue line
enclosed in a blue dashed diamond indicates the mean value ± SEM.
According to Wilcoxon’s Z test, the levels of statistical significance of
twice-positive vs. twice-negative (control) samples are: B-MYB (top panel),
P = 0.0023; CIP-2a (middle panel), P < 0.0004; and TKTL1 (bottom panel),
P < 0.0001 (see Table 2).
Sensitivity, 0.833 Specificity, 87.9% Accuracy, with a Likelihood
Ratio (+) of 5.60, Predictive Value (+) of 0.97, and Cost of
0.103) (Table 3). Moreover, the suitability of TKTL1 and CIP-2a
as useful clinical biomarkers was strengthened by their very high
Odd Ratio values (i.e., the measures of the association between
a risk factor and a disease) (48, 49), i.e., CIP-2a, 33.333; and
TKTL1, 70.000. In keeping with this, the ODTs (51) of the specific
band densitometric integrated intensity values (xE4) were: CIP-
2a, 2380 with a false positive (FP) proportion of 0.231 and a
false negative (FN) proportion of 0.091; and TKTL1, 1720 with a
FP proportion of 0.167 and a FN proportion of 0.067 (Figure 4
Middle and Bottom Panels; Table 3). Thus, the ODT values
of TKTL1 and CIP-2a gained from uterine cervical epithelium
scrapings could have a direct clinical significance as they would
allow to pinpoint the twice-positive patients with a significant
risk of active oncoprogression.
An assessment of how the probability of HR-HPV-driven
active oncogenesis changed with increasing densitometric values
of B-MYB, CIP-2a, and TKTL1 in the cervical epithelium
scrapings and its statistical level of significance was carried out
via Logistic Regression (54) combined with Likelihood Ratio Test
(LTRs or Effect of model) (55). Figure 5 displays the respective
fitted Logistic Regression curves indicating the Log Odds ratio
(the Logit) of the probability of the oncogenic outcome in
relation to increasing densitometric values of each protein in
the cervical leftovers examined. Table 4 reports the respective
β0 and β1x Logistic Regression parameters estimates, with their
corresponding 95% CIs, and SEs.
The LTR tests demonstrate that in all the three protein
instances, the Log Likelihood (or the Deviance from the
theoretical best fit) of the Full Model with all the β0 +
β1x predictor data was significantly smaller than the Log
Likelihood of the Null Model with only the β0 intercept
and no β0 + β1x predictor data (Table 5). Therefore, the
predictor significantly improved the Model fit, meaning that
the increasing densitometric values of the three proteins tested
in scraped cervical epithelium samples of patients with an
ASCUS/LSIL cytology diagnosis could significantly impact on
the outcome of active HR-HPV-driven oncogenesis. Hence,
though having different degrees of clinical translatability, B-
MYB, CIP-2a, and TKTL1 are biomarkers of HR-HPV-driven
risk of disease progression which can be detected in cervical
epithelium scrapings with a LSIL/ASCUS cytological diagnosis.
Finally, a pilot study involving six HR-HPV DNA-negative
cervical epithelial scrapings with a generic cytological diagnosis
of inflammation but with a negative result of the complete
TVAG (Trichomonas, Candida, Bacterial vaginosis, Chlamydia,
and Mycoplasma) test showed that no significant difference
could be detected in the expression of TKTL1, CIP-2a, and B-
MYB proteins and in ROC curve and Logistic Regression/LRT
diagnostic parameters vs. 16 double-negative control samples
(data not shown). Though preliminary, these findings further
strengthen the specificity of TKTL1 and CIP-2a as robust
biomarkers of HR-HPV-driven active oncogenesis detectable in
cervical LSIL/ASCUS scrapings.
Clinical Three-Year Follow-Up Results
A total of 13 patients (50%) of twice-positive patients,
whose TKTL, CIP-2A, and B-MYB markers values were
above corresponding OTDs (Figure 4 Middle and Bottom
Panels; Table 3), compliantly underwent a scheduled enrollment
colposcopy coupled with cervical biopsy during the following
three years in order to discriminate benign from precancerous
lesions. In this group, 11 women (84.6%) received a positive
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TABLE 2 | Densitometric integrated intensity values (xE4) of specific protein bands.
Putative biomarker Twice-negative group (CTR)* Twice-positive group** % Change vs. CTR P vs. CTR
B-MYB 344.7 ± 82.5 (n = 16) 1609.2 ± 428.7 (n = 26) +366.8 =0.0023
CIP-2a 2,387.5 ± 332.1 (n = 16) 18,384.6 ± 5,139.3 (n = 26) +670.0 <0.0001
TKTL1 874.7 ± 166.0 (n = 16) 12,786.7 ± 3,454.8 (n = 26) +1361.8 <0.0001
*CTR, controls. **LSIL/ASCUS and HR-HPV DNA-positive samples.
histological diagnosis: the most frequent histological upshot was
CIN1 (n = 5; 38.5% of total cases), followed by CIN2+ (n = 4;
30.8% of total cases) and by CIN2 (n = 2; 15.4% of total cases).
These follow-up histology results strengthen the view that the
biomarkers we analyzed in the cervical scrapings are endowed
with a risk predictive value of disease progression.
DISCUSSION
The sexually transmitted oncogenic HPVs are a real bane of
human life. It is estimated that in the USA from 28 to 46%
of the women under 25 years have been or are infected with
HPVs; novel infections are ∼6.2 million per year; chronic HPV
carriers are ∼20 million; histopathology reveals that ∼330.000
women present a high-grade (CIN 2/3) cervical dysplasia, and
∼1.4 million a low-grade (CIN 1) one; and ∼3,700 women die
of cervical carcinoma each year; of course, worldwide data have
a much greater impact (4, 58). Presently, cervical carcinoma-
preventive screenings are regularly performed every 2–3 years
in Western countries. Notably, HR-HPV-16 and -18 subtype
infections cause 71% of all the cervical carcinomas (11). This
figure rises to 90% when HPV-6, -11, -16, -18, -31, -33, -45, -
52, and -58 infections are brought in (58). Reportedly, multiple
HPV types are found in low-grade cervical lesions, but in high-
grade lesions HPV-16 and -18 types prevail (28, 57, 59). As
data in Table 1 show, HP-16, -51, -52, -56, and -18 were in
decreasing order the most prevalent subtypes in twice-positive
cervical epithelium samples, and the identification of multiple
infecting HPV DNA subtypes in the same specimen occurred in
58.3% of the samples.
Most important, HR-HPVs can drive the development of
cancers in both sexes at the level of vulva, anus, penis, prostate,
oropharynx, skin, and neck, particularly in HIV-infected patients
(28, 60–62). Moreover, HPV infections’ social impact is striking
due to (i) emotional reactions of the patients and family members
aroused by the awareness of the HR-HPVs infection and by the
reiteration of follow-up screenings; and to (ii) growing health
service diagnostic and care costs (63). In HR- or LR-HPV-
infected women, cytological screening identifies the presence of
LSIL or HSIL or ASCUS lesions (14, 16, 64–66). The triage of
LSIL/ASCUS-diagnosed patients is problematic because not only
of the huge numbers involved but also of the lack of generally
accepted management protocols. In addition, follow-up patients
may let slip their tests; and faulty cytology screening results
or incomplete or false-negative HR-HPV genotyping (for LR-
HPV subtypes no commercial diagnostic kits are available) may
fail to spot patients with a HPV-driven oncogenic progression
(17, 19–22, 67). To solve this diagnostic problem, a proper
and fast triage of ASCUS/LSIL cervical lesions particularly
in young women would require a third leg, i.e., the assay
of a novel biomarker(s) objectively predicting the risk of an
active HR-HPV-driven disease and might pinpoint the patients
needing a quick colposcopy referral besides being clinically useful
worldwide including the underdeveloped countries (4, 11, 62).
In this regard, several biomarker quests have been undertaken.
Co-detection of p16 and Ki67, two well-known surrogate
biomarkers of cell-cycle de-regulation, was initially suggested to
unmask HPV-induced oncogenic transformation (68, 69). More
recently, Nuovo et al. (70) identified as putative biomarkers
importin-β, exportin-5, Mcl1, and cFlip, the expression of
which is raised in CIN 1/2 histopathology lesions. In turn,
Markovic et al. (71) reported as a useful metabolic biomarker
the expression of Cervical Acid Phosphatase (CAP) by epithelial
cells in Pap smears which antecedes suspicious morphological
changes. Gomih et al. (72) showed that an increased methylation
of IGF2AS and PEG10 gene regions associates with a chance
of CIN 1 → CIN 2 progression. Also, Bhatia et al. (73)
suggested a chemokine pattern (i.e., CCL2, CCL3, CCL4, CXCL1,
CXCL8, and CXCL12) assessed in cervical liquid-based cytology
samples as a biomarker revealing precancerous cervical lesions.
Moreover, Jin et al. (74) reported that the combined enzyme–
linked immunosorbent detection of Sialyl Lewis A and HPV-
16 L1 improved the ability to distinguish CIN 1, CIN 2, CIN
3 grades and cancer groups patients from normal subjects.
Most recently, Jin et al. (74, 75) looked for (i) autoantibodies
directed against Cancer Antigens 19-9 (CA19-9) and 15-3
(CA15-3), carcinoembryonic antigen (CEA), c-Myc, p53, heat
shock proteins (Hsp)27 and Hsp70, in the sera of HPV-infected
patients; and (ii) for six tumor-associated proteins, of which
combinations of Sialyl Lewis A and p53 would discriminate
cancer from normal condition in exfoliated cervical cells. Finally,
Li et al. (76) suggested to detect CIN 2+ stages via PAX 1 gene
methylation analysis in the triage of ASCUS/LSIL cases.
We independently devised to directly test the worth as
biomarkers of three proteins as HPV-oncogenesis risk beacons
in cervical epithelium scrapings from “twice-positive” patients,
that is having a LSIL/ASCUS cytological diagnosis and a
demonstrated and identified HR-HPV-DNA genotype infection
as compared to “twice-negative,” that is both Pap smear test-
negative and HR-HPV DNA-negative patients. The expression
of the three putative protein biomarkers we evaluated, i.e.,
B-MYB, CIP-2A, and TKTL1, was known to increase in
histopathology sections of CIN2+ and of cervical carcinoma
cones (29–32).
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FIGURE 3 | The receiver operating characteristic (ROC) curve analysis of the
putative biomarker proteins B-MYB (A), CIP-2a (B), and TKTL1 (C). Details
concerning the several diagnostic parameters reckoned from each ROC curve
are reported in Table 3 (q. v.). In all three panels the value of the area under the
curve (AUC) is shown between brackets as well as the no discrimination
(chance) line joining the bottom left angle with the top right angle, the area of
which is 0.5. In all the three instances the AUC values significantly differ
(P < 0.0001) from the no discrimination (chance) area value (see also Table 3).
TPF, true positive fraction or Sensitivity. FPF, false positive fraction
(1-Specificity).
TABLE 3 | Diagnostic statistic parameter values for each putative biomarker
protein.
Putative biomarker B-MYB CIP-2a TKTL1
ROC curve AUC ± SEM 0.788 ± 0.0724 0.885 ± 0.0578 0.937 ± 0.0383
AUC 95% CI 0.647–0.930 0.771–0.998 0.862–1.012
AUC DeLong Z statistics 3.99 6.66 11.4
AUC P vs. chance* <0.0001 <0.0001 <0.0001
Youden’s J index 0.472 0.678 0.833
Optimal decision threshold
(ODT)**
800 2,380 1,720
% Accuracy at ODT 68. 5 85.7 87.9
Sensitivity at ODT 0.913 0.909 0.933
Specificity at ODT 0.538 0.769 0.833
FP proportion at ODT 0.462 0.231 0.167
FN proportion at ODT 0.067 0.091 0.067
Likelihood ratio (+) at ODT 2.02 3.94 5.60
Likelihood ratio (-) at ODT 0.12 0.12 0.08
Predictive value (+) at ODT 0.48 0.64 0.78
Predictive value (-) at ODT 0.95 0.95 0.97
Odds Ratio value at ODT 16.333 33.333 70.000
Cost at ODT 0.189 0.140 0.103
*Chance area = 0.5. **ODT, values of specific protein band densitometric integrated
intensity (xE4).
In more detail, B-MYB is a DNA-binding transcription
factor, the expression and transcriptional activity of which
increase in cells progressing from G1 phase to S phase (or
DNA synthesis) of the mitotic cycle. Immunohistochemically,
being weakly expressed B-MYB is hard to detect in most
normal cervical epithelial cells. Conversely, B-MYB is over
expressed and localizes in the cell nuclei of CIN 2+,
cervical glandular intraepithelial neoplasia, and invasive cervical
carcinoma specimens (13, 29, 33). B-MYB associates with
the HPV E7 protein and interacts with phosphorylated
retinoblastoma protein (pRb), a tumor suppressor protein, and
with p107, a pRb-related protein (13).
In turn, CIP-2a promotes tumorigenesis and, in general,
tumor progression by inhibiting the activity of protein
phosphatase 2A (PP2A)—a prerequisite for the oncogenic
transformation of human cells—and by stabilizing c-MYC in
different tumors. CIP-2A is overexpressed in cervical carcinomas
as it positively correlates with HPV-16 E6 and E7 proteins
expression in CIN3 and cervical cancer tissues and cells (33).
CIP-2a expedites the G1/S transition by modulating Cdk1
and Cdk2 activities in a B-MYB–dependent manner. Indeed,
B-MYB might be the downstream target of CIP-2a, since CIP-2a
silencing inhibited the expression of B-MYB in human cervical
SiHa cancer cells (34, 35). CIP-2A identification in HPV-
associated cancers implies the clinical prominence of this protein
as a cancer biomarker and a potential therapeutic target (30).
Finally, TKTL1 is a key enzyme in the pentose phosphate
pathway, which plays as a crucial role in the progression of
cervical neoplasia (31). TKTL1 expression increases in CIN 2/3
or frank neoplasia stages and in neoplastic HeLa cells (32).
The present findings prove that our method of preserving
cervical epithelium scraping leftovers to obtain from them
integral protein lysates brings about results agreeing with
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FIGURE 4 | The concurrent changes in the proportion values of Sensitivity,
Specificity, and Youden’s J index (Youden’s statistic) in relation to increasing
densitometric integrated intensity values (xE4) of each specific protein band
(A-C) examined. Optimal Decision Thresholds (ODTs) of the densitometric
intensity values for each putative biomarker tested are indicated by vertical
dashed lines and coincide with the highest value of the corresponding
Jouden’s J index.
histopathological data reported in the Literature (29–35).
The procedures we used are simple and the results highly
reproducible. Hence, TKTL1, CIP-2a, and B-MYB testing
could be fully automatized using an ad hoc equipment
and software (this is a current undertaking of our lab).
Arguably, such automated procedures could be used in
mobile labs crisscrossing underdeveloped countries to
screen for HR-HPV-infected women at impending risk of
cervical carcinoma.
FIGURE 5 | The three binary Logistic Regression curves reach convergence
fitting the double-negative (or control) densitometric integrated intensity values
with the double (LSIL/ASCUS and HR-HPV DNA)-positive values for each
specific protein tested (A-C). The curves show the relationship in terms of Log
Odd ratios between a categorical dependent outcome variable (“0” or normal
vs. “1” or active oncogenesis) and the continuously increasing values of the
predictor or independent variable, that is the specific band densitometry
values of each protein studied. The binary Logistic Regression parameters (or
coefficient) estimates of the three curves are reported in Table 4. The results of
the Likelihood Ratio Tests (LRT or Effect of Model) (not shown here: see
Table 5 for details) indicate a statistically significant impact of the increasing
independent predictor (i.e., densitometry values) values on the dependent
outcome “1” (i.e., ongoing HPV-driven oncogenesis).
Previously, the majority cervical carcinoma-related
biomarkers were discovered in histological sections of cervical
tissue cone biopsies taken at colposcopy. Although such
biomarkers may increase the accuracy of the histological
diagnosis of cancer, histopathology cannot be the primary
methodological approach in cervical carcinoma screenings.
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TABLE 4 | Logistic Regression parameters estimates.
Biomarker Parameter Estimate 95% confidence
interval (CI)
SE
B-MYB β0 −0.7578 −1.898 to −0.3820 0.58157
β1x 0.002177 1.066 to 0.00424 1.0565E-03
CIP-2a β0 −3.073 −5.491 to −0.6554 1.2336
β1x 9.226E-04 1.763E-04 to 0.01669 3.8073E-04
TKTL1 β0 −0.9249 −1.916 to −0.06620 0.50565
β1x 2.234E-04 2.137E-05 to 4.255E-04 1.0309E-04
TABLE 5 | Likelihood Ratio Test (LRT or Effect of model).
Biomarker Source Log likelihood** DF* G2 statistic P
B-MYB Difference 5.6899 1 11.38 0.0007
Full model 21.235 39
Null model 26.925 40
CIP-2a Difference 10.388 1 20.78 <0.0001
Full model 12.106 31
Null model 22.494 32
TKTL1 Difference 5.8293 1 11.66 0.0006
Full model 17.679 32
Null model 23.508 33
*DF, degrees of freedom. **, a measure of Deviance from optimal fit (see text).
This would be impractical as it could hardly deal with large
numbers of LSIL/ASCUS bioptic samples particularly in
underdeveloped countries. Conversely, using the very same
cervical epithelium scrapings to perform standard cytology,
HR-HPV DNA genotyping, and biomarker(s), such as TKTL1
and/or CIP-2a expression levels analysis via standard protein
lysates Western immunoblotting and specific band densitometry
is a feasible undertaking.
In keeping with the just mentioned Literature, our present
findings reveal for the first time that it is feasible to detect
an increased expression of TKTL1, CIP-2A, and B-MYB in the
cervical epithelium scrapings of HR-HPV DNA-positive women
having a LSIL/ASCUS cytological diagnosis. Notwithstanding B-
MYB’s weaker expression, its statistically significant diagnostic
indexes make it a still potentially translatable risk predictive
biomarker of HR-HPV-driven disease progression. B-MYB’s
“weakness” may be due to its role as a transcription factor
(33), which does not require its synthesis in huge amounts.
Moreover, B-MYB’s near absence in twice-negative (control)
scraping samples is due to its declining synthesis in the
terminally differentiating cells of the higher layers of the cervical
epithelium (33).
Strengths of this works are: the novel diagnostic approach
using cervical epithelium scraping leftovers; feasible and practical
methodology used for protein expression analysis; use of
biomarkers of the cervical epithelium as objective indicators
of HR-HPV-driven disease; the precise assessment of the ODT
values for each biomarker which reduces to a minimum the size
of false-positive and false-negative findings; and the matching
of the biomarker data with follow up data in 85% of the
compliant patients.
Limitations of this work are: grouping of ASCUS and LSIL
patients in one category because, according to Italian GISCI
directive, LSIL or negative diagnoses have mostly supplanted
the ASCUS one; the relatively small numbers of patients
examined which warrants further studies and follow-ups with
larger cohorts.
In conclusion, our biochemical, statistical and three-
year follow up findings indicate TKTL1, CIP-2A, and
B-MYB as potential robust risk predictive biomarkers
of an active onco-developmental process driven by
HR-HPV subtypes.
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